Anteris Technologies

WAYNE PETERSON

CEO & MANAGING DIRECTOR

(ASX:AVR)

◾ Company Name: Anteris Technologies ◾ Company ASX code: AVR ◾ Key areas: Aortic valve replacement ◾ Key Personnel: Wayne Peterson, CEO & Managing Director | John Seaberg, Chairman ◾ Locations: Australia and United States ◾ Market Cap as of 15/09/22: $347.50M ◾ 52 Week share price as of 15 September: $7.810 - $30.890 ◾ Company Website: anteristech.com

COMPANY PROFILE

Anteris is an Australian structural Heart company focused on creating the world’s most durable heart valve through better science and better design.

The company’s ADAPT® Tissue technology is a true innovation that addresses the critical issue of durability, allowing replacement heart valves to last longer and work better.

Invented in Australia by cardiothoracic surgeon Professor Leon Neethling, the company’s ADAPT® Tissue Treatment is the first and only next-generation technology that removes all potential triggers of inflammation and calcification – the leading causes of heart valve failure, thereby extending the durability of tissue used for making replacement heart valves and other cardiac solutions.

A significant body of peer-reviewed, published evidence over two decades provides strong evidence in support of ADAPT® technology, strongly distinguishing Anteris from its peers.

Calcium deposits are the major cause of aortic stenosis (AS) - a highly prevalent disease that stiffens and narrows the heart valve opening. Without treatment, severe AS can lead to heart failure and death.

Anteris’ second major innovation, the DurAVR™ THV System (Transcatheter Heart Valve) has been designed in partnership with an Advisory Board of the world’s most influential and experienced interventional cardiology pioneers.

DurAVR™ THV is the first and only 3-D shaped, single-piece aortic valve in the world for minimally invasive TAVR, specifically designed to mimic native aortic valve form and function.

Patients deemed unsuitable for a gruelling open-heart surgery could now have their heart valves replaced in a non-invasive TAVR procedure lasting about 30 minutes with new generation transcatheter aortic valve technology like DurAVR™ THV.

The combination of durability provided by ADAPT™ Tissue and the unique design of DurAVR™ optimises blood flow and has the potential to restore normal pre-disease blood flow and deliver a functional cure to aortic stenosis patients.

The DurAVR™ THV valve addresses the needs of tomorrow’s younger and more active aortic stenosis patients, by delivering the durability needed to last the remainder of a patient’s lifetime.

The DurAVR™ THV First-inhuman study demonstrated remarkable flow characteristics and patient outcomes. “DurAVR™ has been rationally engineered to provide ease of implantation of the valve for the doctor, immediate haemodynamic benefit for the patient post-implantation, and the potential to provide a long-term durable effect which is of utmost importance when treating younger, low-risk patients”, commented Dr. Vinnie Bapat, MD, Lead Investigator and Cardiothoracic Surgeon at the Minneapolis Heart Institute.

Anteris’ third innovation is the ComASUR™ TF Delivery System. It is aimed at providing physicians the ability to deliver precision alignment of new heart valves to the patient’s native valve. There is growing evidence that malalignment impacts device performance and leads to negative clinical outcomes.

The market opportunity for Anteris is huge, with the aortic valve replacement market predicted to grow by 12% CAGR to US$14 billion by 2028.

Anteris is managed by a team of experts. CEO Wayne Peterson has held numerous, senior positions in multinational companies and has lived in seven countries during the past 25 years.

His experience includes managing multibillion-dollar businesses throughout the world, including mergers, integrations, acquisitions and restructures.

Chairman John Seaberg meanwhile, was the founder, chairman and CEO of NeoChord Inc, a venture capital-backed company commercialising technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques.

KEY INVESTMENT HIGHLIGHTS

◾ Successfully completed first-in-human DurAVR™ THV System study at the Tbilisi Heart and Vascular Clinic in Georgia. Six-month follow-up demonstrating excellent results with an 86% improvement in haemodynamics. ◾ Expansion of Medical Advisory Board with the appointments of Australian interventional cardiologists Dr Karl Poon and Associate Professor Dion Stub. ◾ $US20 million ($A27.6 million) placement of 1,840,000 new shares to Perceptive Life Sciences Master Fund at $A15 per share.